Interaction Checker

Interacciones de Sapropterina

Sapropterina (Kuvan, Javygtor) tiene 15 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 0; moderadas: 15; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones moderadas (15)

  • Ácido fólico (folato)Vitaminas y mineralesModerada

    Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim) Clinical Impact In vitro and in vivo nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. (etiqueta de Sapropterina, Interacciones medicamentosas)

  • Ácido valproicoanticonvulsivoModerada

    Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim) Clinical Impact In vitro and in vivo nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. (etiqueta de Sapropterina, Interacciones medicamentosas)

  • AmantadinaanticolinérgicoModerada

    Interaction with Levodopa : Seizures, over-stimulation or irritability may occur; monitor patients for a change in neurologic status. (etiqueta de Sapropterina, Advertencias y precauciones)

  • Avanafiloinhibidor de la PDE5Moderada

    Drugs Affecting Nitric Oxide‑Mediated Vasorelaxation (e.g., PDE-5 inhibitors) : Potential for vasorelaxation; monitor blood pressure. (etiqueta de Sapropterina, Interacciones medicamentosas)

  • Carbidopa y levodopafármaco dopaminérgicoModerada

    Interaction with Levodopa : Seizures, over-stimulation or irritability may occur; monitor patients for a change in neurologic status. (etiqueta de Sapropterina, Advertencias y precauciones)

  • Carbidopa, levodopa y entacaponafármaco dopaminérgicoModerada

    Interaction with Levodopa : Seizures, over-stimulation or irritability may occur; monitor patients for a change in neurologic status. (etiqueta de Sapropterina, Advertencias y precauciones)

  • FenobarbitalbarbitúricoModerada

    Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim) Clinical Impact In vitro and in vivo nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. (etiqueta de Sapropterina, Interacciones medicamentosas)

  • Fenobarbital, hiosciamina, atropina y escopolaminabarbitúricoModerada

    Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim) Clinical Impact In vitro and in vivo nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. (etiqueta de Sapropterina, Interacciones medicamentosas)

  • Levodopafármaco dopaminérgicoModerada

    Interaction with Levodopa : Seizures, over-stimulation or irritability may occur; monitor patients for a change in neurologic status. (etiqueta de Sapropterina, Advertencias y precauciones)

  • MetotrexatoinmunosupresorModerada

    Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim) Clinical Impact In vitro and in vivo nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. (etiqueta de Sapropterina, Interacciones medicamentosas)

  • Sildenafiloinhibidor de la PDE5Moderada

    Drugs Affecting Nitric Oxide‑Mediated Vasorelaxation (e.g., PDE-5 inhibitors) : Potential for vasorelaxation; monitor blood pressure. (etiqueta de Sapropterina, Interacciones medicamentosas)

  • Sulfametoxazol y trimetoprimasulfonamidaModerada

    Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim) Clinical Impact In vitro and in vivo nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. (etiqueta de Sapropterina, Interacciones medicamentosas)

  • Tadalafiloinhibidor de la PDE5Moderada

    Drugs Affecting Nitric Oxide‑Mediated Vasorelaxation (e.g., PDE-5 inhibitors) : Potential for vasorelaxation; monitor blood pressure. (etiqueta de Sapropterina, Interacciones medicamentosas)

  • TrimetoprimaantibióticoModerada

    Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim) Clinical Impact In vitro and in vivo nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. (etiqueta de Sapropterina, Interacciones medicamentosas)

  • Vardenafiloinhibidor de la PDE5Moderada

    Drugs Affecting Nitric Oxide‑Mediated Vasorelaxation (e.g., PDE-5 inhibitors) : Potential for vasorelaxation; monitor blood pressure. (etiqueta de Sapropterina, Interacciones medicamentosas)

Compruebe Sapropterina frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.